Bristol Myers Squibb Announces Dividend Increase
Get Alerts BMY Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2023 to stockholders of record at the close of business on January 6, 2023.
This quarterly dividend represents a 5.6% increase over last year’s quarterly dividend rate of fifty-four cents ($0.54) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2023 is $2.28 per share. This marks the fourteenth consecutive fiscal year that the company has increased its dividend and the 91st consecutive year that the company has paid a dividend.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 1, 2023 to stockholders of record at the close of business on January 31, 2023.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208006029/en/
Media:
[email protected]
Investors:
[email protected]
Source: Bristol Myers Squibb
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
- Weekly progress on share repurchase program to cover share plans and reduce capital
- Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share